Nanobodies (Nbs) are increasingly recognized as valuable biological molecules with
significant potential in the field of diagnostics. Their unique physiochemical characteristics …

Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for the
diagnosis and treatment of multiple diseases. Radiopharmaceutical therapy, which directly …

Abstract Purpose Claudin18. 2 (CLDN18. 2) is a novel target for diagnosis and therapy of
gastrointestinal cancer. This study aimed to evaluate the safety and feasibility of a novel …

Simple Summary Cancer is a leading cause of death worldwide, accounting for nearly one
in six deaths. The most common cancers are lung, breast, colon, rectum and prostate …

Abstract Claudin 18.2 (CLDN18. 2) is an emerging target for the treatment of CLDN18. 2-
expressing cancers such as gastric and pancreatic cancers. Cell and antibody therapies …

Radiopharmaceuticals play a critical role in nuclear medicine, providing novel tools for
specifically delivering radioisotopes for the diagnosis and treatment of cancers. As the …

Claudin18. 2 (CLDN18. 2), due to its high expression in various gastric cancer tissues, is
considered an optimal target for antitumor drug molecules. In this study, we obtained the …

Abstract Purpose Claudin 18.2 (CLDN18. 2), due to its highly selective expression in tumor
cells, has made breakthrough progress in clinical research and is expected to be integrated …

Recent global clinical trials have shown that CLDN18. 2 is an ideal target for the treatment of
gastric cancer and that patients with high CLDN18. 2 expression can benefit from targeted …

Purpose Gastric cancer (GC), one of the most prevalent and deadliest tumors worldwide, is
often diagnosed at an advanced stage with limited treatment options and poor prognosis …